A top-selling but controversial Abbott Laboratories (ABT) cholesterol drug faces a key test when a U.S. government study ending next month shows whether it actually prevents heart attacks and related disease.
Abbott's TriCor is known to improve levels of cholesterol and related substances, but there is skimpy proof this translates into better cardiovascular outcomes - even though the...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Abbott Heart Drug Faces Key Test In Large US Study
Please enter your email address and password. Not a member? Join now
